Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GCM-101
- Development stage
- Preclinical
- Lead developer
- Gencellmed
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral
01
Overview
GCM-101 is an engineered herpes simplex virus type 1 (HSV-1)-based oncolytic virus developed by Gencellmed for the treatment of various solid tumors, including ovarian, prostate, pancreatic, breast, lung, and colon cancers. The virus utilizes a "Double Retargeting Technology" involving an HVEM-scFvEpCAM adapter and a modified gH-scFvEpCAM to specifically target Epithelial Cell Adhesion Molecule (EpCAM)-expressing tumor cells. To ensure tumor-selective replication, the virus is controlled by the human telomerase reverse transcriptase (hTERT) promoter. Additionally, GCM-101 is engineered to secrete immunostimulatory cytokines, specifically Interleukin-12 (IL-12), Interleukin-7 (IL-7), and Fms-related tyrosine kinase 3 ligand (FLT3LG), to enhance the anti-tumor immune response. It is currently in preclinical development.
- Other names
- GCM-101GCM101GCM 101
02
Targets
EPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on GCM-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GCM-101.